DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Ifetroban is an investigational drug.
There have been 9 clinical trials for Ifetroban. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2011.
The most common disease conditions in clinical trials are Respiratory Tract Diseases, Respiration Disorders, and Asthma, Aspirin-Induced. The leading clinical trial sponsors are Cumberland Pharmaceuticals, Jeffrey Rade, and American Heart Association.
There are six hundred and thirty-eight US patents protecting this investigational drug and four international patents.
Recent Clinical Trials for Ifetroban
|Thromboxane Receptor Antagonist to Improve Endothelial Cell Function||American Heart Association||Phase 2|
|Thromboxane Receptor Antagonist to Improve Endothelial Cell Function||Cumberland Pharmaceuticals||Phase 2|
|Thromboxane Receptor Antagonist to Improve Endothelial Cell Function||Jeffrey Rade||Phase 2|
Top disease conditions for Ifetroban
Top clinical trial sponsors for Ifetroban
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ifetroban||See Pricing||Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors||Bristol-Myers Squibb Company (Princeton, NJ)||See Pricing|
|Ifetroban||See Pricing||Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer||Capella Therapeutics, Inc. (San Diego, CA)||See Pricing|
|Ifetroban||See Pricing||Compositions and methods of treating cardiac fibrosis with ifetroban||Cumberland Pharmaceuticals Inc. (Nashville, TN) Vanderbilt University (Nashville, TN)||See Pricing|
|Ifetroban||See Pricing||Substituted biaryl sulfonamides and the use thereof||NovoMedix, LLC (San Diego, CA)||See Pricing|
|Ifetroban||See Pricing||Compositions and methods of treating muscular dystrophy with thromboxane-A.sub.2 receptor antagonists||Cumberland Pharmaceuticals, Inc. (Nashville, TN) Vanderbilt University (Nashville, TN)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Ifetroban||European Patent Office||2766345||2031-10-14||See Pricing|
|Ifetroban||European Patent Office||2899183||2031-10-14||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|